8月11日，Hims & Hers Health盘中下跌7.3%，报29.52美元/股，成交额4890.46万美元。
消息面上，公司发布第二季度财报，每股亏损0.37美元，远超市场预期的0.03至0.05美元亏损，较去年同期每股盈利0.17美元大幅恶化，由盈转亏。尽管营收同比增长38%至7.53亿美元，订阅用户增至约289万，公司亦上调全年营收指引至31亿至33亿美元，但毛利率从去年同期的76%骤降至64%，CFO表示国际业务拓展及品牌GLP-1减肥药销售拖累利润率，并预计毛利率将长期维持在历史低位以下，巨额亏损令投资者信心承压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.